Free shipping on all orders over $ 500

Enavogliflozin

Cat. No. M21456
Enavogliflozin Structure
Synonym:

DWP-16001

Size Price Availability Quantity
5mg USD 578  USD578 In stock
10mg USD 880  USD880 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Enavogliflozin (DPW-16001), an antidiabetic compound, is a first class selective sodium-glucose cotransporter-2 (SGLT-2) inhibitor with oral activity.

Chemical Information
Molecular Weight 446.92
Formula C24H27ClO6
CAS Number 1415472-28-4
Solubility (25°C) DMSO ≥ 60 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] Min-Soo Kim, et al. Pharmaceutics. Physiologically Based Pharmacokinetic Modelling to Predict Pharmacokinetics of Enavogliflozin, a Sodium-Dependent Glucose Transporter 2 Inhibitor, in Humans

[2] Kyung-Soo Kim, et al. Diabetes Metab. Efficacy and safety of enavogliflozin versus dapagliflozin added to metformin plus gemigliptin treatment in patients with type 2 diabetes: A double-blind, randomized, comparator-active study: ENHANCE-D study

[3] Soo Heon Kwak, et al. Diabetes Obes Metab. Efficacy and safety of enavogliflozin, a novel SGLT2 inhibitor, in Korean people with type 2 diabetes: A 24-week, multicentre, randomized, double-blind, placebo-controlled, phase III trial

[4] Kyung Ah Han, et al. Diabetes Metab J. Efficacy and Safety of Enavogliflozin versus Dapagliflozin as Add-on to Metformin in Patients with Type 2 Diabetes Mellitus: A 24-Week, Double-Blind, Randomized Trial

[5] Minyeong Pang, et al. Pharmaceutics. Pharmacokinetics and Tissue Distribution of Enavogliflozin in Mice and Rats

Related SGLT Products
Tianagliflozin

Tianagliflozin is an SGLT2 inhibitor that may be used in studies related to type 2 diabetes.

JTT-662

JTT-662 is an SGLT1 inhibitor that can be used in studies related to type 2 diabetes.

JP-2266

JP-2266 is a dual SGLT1/2 inhibitor that can be used in studies related to diabetes.

Tofogliflozin

Tofogliflozin(CSG-452) is a potent and highly specific sodium/glucose cotransporter 2(SGLT2) inhibitor with Ki values of 2.9, 14.9, and 6.4 nM for human, rat, and mouse SGLT2.

Mizagliflozin

Mizagliflozin (DSP-3235 free base) is a potent, orally active and selective SGLT1 inhibitor, with a Ki of 27 nM for human SGLT1. Mizagliflozin displays 303-fold selectivity over SGLT2. Mizagliflozin is used as an antidiabetic agent that can modify postprandial blood glucose excursion. Mizagliflozin also exhibits potential in the amelioration of chronic constipation.

  Catalog
Abmole Inhibitor Catalog




Keywords: Enavogliflozin, DWP-16001 supplier, SGLT, inhibitors, activators


Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.